Insider trade

Gilead Sciences (GILD): CFO sold ~$782K

Andrew D Dickinson, CFO at Gilead Sciences, sold ~$782K of Gilead Sciences shares.

~$782K
Approx. value · 8,500 sh @ $91.96
132K
Holds after · shares reported
Traded
Dec 16, 2024
Filed
Dec 17, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 6, 2024Insider · 2 peopleInsiders: 3 sales (~$2.8M)
  2. Nov 13, 2024Layoff notice · SeattleLayoff notice filed in WA: 72 employees
  3. Nov 22, 2024FDAFDA drug approval: Trodelvy
  4. Nov 25, 2024FDAFDA drug approval: Sunlenca
  5. Nov 25, 2024FDAFDA drug approval: Sunlenca
  6. Nov 26, 2024InsiderDirector sold ~$620K of GILD shares in the open market
  7. Nov 27, 2024Insider · 1 personInsiders: 5 sales (~$15.1M)
  8. Nov 29, 2024Insider · 1 personInsiders: 2 sales (~$23.1M)
  9. Dec 16, 2024 · this disclosureInsiderCFO sold ~$782K of GILD shares in the open market

What came next

  1. Dec 24, 2024CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. Jan 15, 2025InsiderCFO sold ~$228K of GILD shares in the open market
  3. Jan 31, 2025InsiderCFO sold ~$13.8M of GILD shares in the open market
  4. Feb 12, 2025InsiderCFO sold ~$14.1M of GILD shares in the open market
  5. Feb 18, 2025InsiderCFO sold ~$260K of GILD shares in the open market
  6. Feb 19, 2025FDAFDA drug approval: Odefsey
  7. Feb 19, 2025FDAFDA drug approval: Odefsey
  8. Mar 7, 2025FDARecall: Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Therapeutics LLC an affiliate of Gilead Sc…
  9. Mar 7, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  10. Mar 10, 2025Insider · 1 personInsiders: 2 sales (~$2.1M)
  11. Mar 10, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  12. Mar 17, 2025InsiderCFO sold ~$276K of GILD shares in the open market
  13. Mar 31, 2025CongressDisclosed purchase of GILD — reported range $15,001 - $50,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Andrew D Dickinson, Chief Financial Officer

The full history of Andrew D Dickinson, Chief Financial Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Gilead Sciences (GILD) insider traded, and how much?

Andrew D Dickinson, CFO at Gilead Sciences, sold ~$782K of Gilead Sciences shares. 8,500 shares at $91.96.

When did it happen, and when was it made public?

Traded: Dec 16, 2024. Filed: Dec 17, 2024. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Gilead Sciences recently?

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.

Does this mean GILD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data